CAR-T Meeting 2022 | Safety considerations in CAR-T therapy: patient selection and side effects
Hermann Einsele
• 15 Feb 2022
Hermann Einsele, MD, FRCP, University of Würzburg, Würzburg, Germany, shares guidelines on patient selection and patient follow-up after treatment with chimeric antigen receptor T-cell (CAR-T) therapy. Prof. Einsele explains that patients with comorbidities including cardiovascular and pulmonary diseases, as well as renal, liver or hematopoietic dysfunction should not receive CAR-T therapy. It is also important to avoid exposing patients to lymphodepleting treatments prior to leukapheresis. In addition, clinicians should be aware of side effects that can occur long after treatment with CAR-Ts. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
